Conditions: Porphyria Cutanea Tarda
Keywords: Exjade PCT Study PCT Study Porphyria Cutanea Tarda
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda.

Primary objective - the elimination of all blistering within 6 months of treatment.

Secondary objective - decrease in total body iron levels.

Detailed description:
Phlebotomy is the standard therapy for Porphyria Cutanea Tarda (PCT), but it can be inconvenient and cause anemia in some patients.

Deferasirox is a new class of tridentate iron chelators with high affinity and selectivity for iron. The medication is administered orally, which if effective for PCT would make it a more convenient and possibly more tolerable option for patients.

Arms:
arm 1: None

Interventions: intervention 1: Deferasirox
Intervention descriptions: intervention 1: 250 mg of deferasirox once daily for 6 months

Protocol document: